|
Citation
|
Feder KA, Harris SJ, Byrne L, Miller SM, Sodder S, Berman V, Livingston A, Edwards J, Hartman S, Sugarman OK, Shah H, Xu J, Raikes J, Gattine S, Saloner B. Drug Alcohol Depend. 2023; 250: e110879. |
|
Abstract
|
BACKGROUND: In July 2021, Vermont removed all criminal penalties for possessing 224mg or less of buprenorphine.
METHODS: Vermont residents (N=474) who used illicit opioid drugs or received treatment for opioid use disorder in the past 90 days were recruited for a mixed-methods survey on the health and criminal legal effects of decriminalization. Topics assessed included: motivations for using non-prescribed buprenorphine, awareness of and support for decriminalization, and criminal legal system experiences involving buprenorphine. We examined the frequencies of quantitative measures and qualitatively summarized themes from free-response questions.
RESULTS: Three-quarters of respondents (76%) reported lifetime use of non-prescribed buprenorphine. 80% supported decriminalization, but only 28% were aware buprenorphine was decriminalized in Vermont. Respondents described using non-prescribed buprenorphine to alleviate withdrawal symptoms and avoid use of other illicit drugs. 18% had been arrested while in buprenorphine, with non-White respondents significantly more likely to report such arrests (15% v 33%, p<0.001).
CONCLUSION: Decriminalization of buprenorphine may reduce unnecessary criminal legal system involvement, but its health impact was limited by low awareness at the time of our study.
Language: en |